Industry News — August 2026

The subgroup data is the real story: if silencers add nothing once patients are already stabilized, the industry's drift toward stabilizer-plus-silencer combos loses its evidence base, and AZ/Ionis must reposition Wainua as monotherapy — a much smaller, harder-to-sell market. That's a strategic problem, not just a trial miss, and it makes Intellia's one-and-done knockdown pitch relatively more attractive. Alnylam's rebuttal (deeper knockdown, a bigger trial) is the self-interested defense you'd expect from a company facing guilt-by-association, resting on cross-trial comparisons Alnylam itself is asserting, not independent data — treat "deeper knockdown" as a hypothesis until TRITON-CM reads out. Nucresiran's margin for error just got narrower. Watch prescriber messaging: whoever wins the "silencer as add-on vs. backbone" argument sets ATTR-CM's standard of care.

The economics: $45M upfront against $1B+ in milestones is a cheap call option for Genentech — DualityBio absorbs discovery and Phase 1a risk, and Genentech only pays once DUPAC clears its resistance hurdle. That's a smaller headline number than DualityBio's 2023 BioNTech deal, hinting at either narrower scope or softer terms on partner #2. Strategically, this is Roche/Genentech hedging against a class-wide ceiling: TOP1 payloads underpin nearly the entire current ADC generation, including Enhertu and DualityBio's own BioNTech HER2 asset, so resistance will bite everyone eventually. It also confirms Genentech won't build payload discovery in-house, joining Pfizer/Seagen and AbbVie/ImmunoGen in sourcing ADC innovation from China. For DualityBio, a second nine-figure MNC partner in three years validates the platform model — though whether DUPAC actually beats resistant tumors is still unproven.